Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

HER2-PET Imaging Using 89Zr-trastuzumab in Low HER2-expressing (HER2-low) Breast Cancers

NCT06732336 is registered in ClinicalTrials.gov with Centre de recherche du Centre hospitalier universitaire de Sherbrooke as lead sponsor.

NCT NCT06732336
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06732336 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
HER2-PET Imaging Using 89Zr-trastuzumab in Low HER2-expressing (HER2-low) Breast Cancers
Lead sponsor
Centre de recherche du Centre hospitalier universitaire de Sherbrooke
Phase
Phase 1/2
Overall status
Recruiting
Start date
December 1, 2024
Completion date
March 31, 2027
Enrollment
40 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer metastatic